Cohorte Nationale VIH-2

The secondary objectives are :

* Describe the epidemiological and clinical characteristics of participants infected with HIV-2, and the immuno-virological characteristics of the infection.
* To study the clinical and immunological progression of HIV-2 infection and the prognostic factors of this evolution.
* Study the response to antiretroviral treatment (clinical, immuno-virological) and contribute to the identification of the antiretroviral strategies and combinations most suited to the particularities of the infection.
* Allow an evaluation of the care practices of participants followed in French hospitals
* Provide a bank of clinical-biological data and samples allowing the performance of virological and / or immunological studies on HIV-2 infection.

The follow-up of the participants is different according to the therapeutic status of the participants, naive of antiretroviral treatment or already treated with antiretrovirals.

• Antiretroviral (Drug): Study the response to antiretroviral treatment (clinical, immuno-virological) and contribute to the identification of the antiretroviral strategies and combinations most suited to the particularities of the infection.

Primary outcomes

• Study HIV-2 infection rate in adult patients followed in France [At the baseline]

Secondary outcomes

• The clinical progression of patients infected HIV-2 evaluate by samples: biological examinations [Up to 25 years]: Every 6 months
• The epidemiological parameters and progression of patients infected with HIV-2 evaluate by a questionnaire [Up to 25 years]: Every 6 months
• The rate of immuno-virological charge of the infection evaluate by serology samples [Up to 25 years]: Every 6 months
• Pourcentage of patient with HIV-2 [Up to 25 years]: The prognostic factors of patient evolution are evaluate by biological samples
• Pourcentage of response to antiretroviral treatment evaluate by serology samples [Up to 25 years]
• Pourcentage of good management practices of patients followed in French hospitals evaluate by results [Up to 25 years]: During the procedure

Sex: All, ages: 18 Years to any

Inclusion Criteria:

* HIV-2 infection only, diagnosed by ELISA, confirmed by Western-Blot test,
* Follow-up in consultation or hospitalization in one of the investigating centers,
* Age greater than or equal to 18 years,
* Prolonged follow-up possible, residence in France planned for at least one year,
* Consent to participate,
* Long-term medical care possible for the participant, or by medical aid (AME), or declaration of obtaining AME at the time of inclusion.

Exclusion Criteria:

* HIV-1 infection
* Double HIV-1 + HIV-2 seropositivity

• François Dabis, Pr, MD, Study director, ANRS, Emerging Infectious Diseases